Authors
Latest:
Practical Advice on the Management of Tumor Lysis SyndromeClosing out his discussion on tumor lysis syndrome, Anthony Perissinotti, PharmD, BCOP, shares practical advice on its identification and management.
Latest:
How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEdDr Mekhail discusses the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma.
Latest:
A New Generation of Cytokine-Based Immunotherapy Takes ShapeNearly 40 years after the first cytokine-based therapy was approved for the treatment of patients with hairy cell leukemia, investigators are taking a fresh look at ways to leverage these signaling proteins to enhance immunotherapies and vaccines in other cancers.
Latest:
Find the Job That’s Right for YouThe American Society of Clinical Oncology projects significant shortages of practicing oncologists compared with patients with new cancer diagnoses and existing cancer by 2025.
Latest:
Dr Auletta on the Impact of Post-Transplant Cyclophosphamide in Hematologic MalignanciesJeffery Auletta, MD, discusses the impact of post-transplant cyclophosphamide in hematologic malignancies.
Latest:
Dr Inra on the Role of the Surgeon in Early-Stage Lung CancerMatthew Lawrence Inra, MD, discusses the role of the thoracic surgeon in treatment decision-making for patients with early-stage lung cancer.
Latest:
Future of R/R DLBCLA panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.
Latest:
Atrium Health Levine Cancer Begins Treating Patients with Proton Beam TherapyAtrium Health Levine Cancer will begin treating patients with proton beam therapy.
Latest:
Dr Leypoldt on the Use of Isa-KRd in Newly Diagnosed, High-Risk Multiple MyelomaLisa Leypoldt, MD, discusses findings from the phase 2 GMMG-CONCEPT trial in patients with multiple myeloma.
Latest:
Deciding When to Defer Oncology TreatmentOncologists are challenged to make a different determination when a new patient presents with advanced cancer.
Latest:
Exploring Emerging Data in DLBCLA panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
Latest:
IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed GlioblastomaIGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.
Latest:
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation to Address the Evolved Landscape of EGFR Mutant NSCLCChristine Lovly, MD, PhD, shares data on BDTX-1535, a “masterkey” EGFR inhibitor targeting classical, non-classical, and the C797S resistance mutation in patients with EGFR mutant non-small cell lung cancer (NSCLC), from a presentation at AACR 2024.
Latest:
Drs Gerber and Nwachukwu on the Importance of Streamlining Clinical Research in Cancer CareDavid Gerber, MD, and Chika Nwachukwu, MD, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.
Latest:
Robert L. Ferris, MD, PhD, Appointed Executive Director of UNC Lineberger Comprehensive Cancer CenterRobert L. Ferris, MD, PhD, has been named the executive director of UNC Lineberger Comprehensive Cancer Center and UNC system chief of oncology services.
Latest:
Dr. Vogl on the Utilization of Modakafusp Alfa in Relapsed/Refractory Multiple MyelomaDan Vogl, MD, MSCE, discusses the utilization of modakafusp alfa in relapsed/refractory multiple myeloma.
Latest:
Dr. Lara on Role of Molecular Differences in Disparities in Uterine Serous CarcinomaOliva Lara, MD, discusses the connection between molecular differences and disparities in cancer care in uterine serous carcinomas, as examined in a retrospective cohort study.
Latest:
Drs Edelman and Fleisher on Personalizing and Adapting Treatment Approaches in Clinical TrialsMartin Edelman, MD, and Linda Fleisher, PhD, MPH, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.
Latest:
Dr Cosman on the Potential Utility of MT-302 in TROP-2–Expressing Epithelial CancersRasha Cosman, BSc, MBBS, FRACP, discusses the mechanism of action and potential role for the in vivo mRNA CAR therapy MT-302 in TROP-2–expressing epithelial cancers.
Latest:
ACCC Releases Trending Now in Cancer CareThe Association of Community Cancer Centers today released its annual Trending Now in Cancer Care report, including actionable strategies in 8 key areas.
Latest:
Dr Dima on Real-World Responses With Teclistamab in R/R Multiple MyelomaDanai Dima, MD, discusses real-world responses with teclistamab in relapsed/refractory multiple myeloma.
Latest:
Dr. Spivak on Diagnosing Essential ThrombocythemiaJerry Le Pow Spivak, MD, discusses diagnosing essential thrombocythemia.
Latest:
Final Thoughts on New Developments and Emerging AgentsPanelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.
Latest:
The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and MortalityOne of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.
Latest:
Dr. Kumar on Treatment Considerations with BTK Inhibitors in MCLAnita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.
Latest:
CLL: Final ThoughtsAn expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.
Latest:
Carbone Partner Perspectives: Alcohol: The Carcinogen We’re Not Talking AboutDespite alarming figures and trends, public awareness of alcohol as a carcinogen remains low.
Latest:
Dr. Wildiers on the Final Results of the AIPAC Trial in HR+/HER2- Metastatic Breast CancerHans Wildiers, MD, medical oncologist, Department of Medical Oncology, full professor, Faculty of Medicine, member, Laboratory of Experimental Oncology, University Hospital Leuven, Leuven, Belgium, discusses the final results of the phase 2b AIPAC trial (NCT02614833) in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.
Latest:
Dr. Lee on Selecting a Treatment Approach for Neuroendocrine TumorsYoomi Lee, MD, discusses her process for selecting a treatment approach for patients with neuroendocrine tumors.
.jpg?fit=crop&auto=format)
